

# Measuring Cerebral and Cerebellar Glutathione in Children Using $^1\text{H}$ MEGA-PRESS MRS

 F. Raschke,  R. Noeske,  R.A. Dineen, and  D.P. Auer



## ABSTRACT

**BACKGROUND AND PURPOSE:** Glutathione is an important antioxidant in the human brain and therefore of interest in neurodegenerative disorders. The purpose of this study was to investigate the feasibility of measuring glutathione in healthy nonsedated children by using the  $^1\text{H}$  Mescher-Garwood point-resolved spectroscopy (MEGA-PRESS) sequence at 3T and to compare glutathione levels between the medial parietal gray matter and the cerebellum.

**MATERIALS AND METHODS:** Glutathione was measured using MEGA-PRESS MRS (TR = 1.8 seconds, TE = 131 ms) in the parietal gray matter ( $35 \times 25 \times 20 \text{ mm}^3$ ) of 6 healthy children ( $10.0 \pm 2.4$  years of age; range, 7–14 years; 3 males) and in the cerebellum of 11 healthy children ( $12.0 \pm 2.7$  years of age; range, 7–16 years; 6 males). A postprocessing pipeline was developed to account for frequency and phase variations in the edited ON and nonedited OFF spectra. Metabolites were quantified with LCModel and reported both as ratios and water-scaled values. Glutathione was quantified in the ON-OFF spectra, whereas total NAA, total Cho, total Cr, mIns, Glx, and taurine were quantified in the OFF spectra.

**RESULTS:** We found significantly higher glutathione, total Cho, total Cr, mIns, and taurine in the cerebellum ( $P < .01$ ). Glx and total NAA were significantly higher in the parietal gray matter ( $P < .01$ ). There was no significant difference in glutathione/total Cr ( $P = .93$ ) between parietal gray matter and cerebellum.

**CONCLUSIONS:** We demonstrated that glutathione measurement in nonsedated children is feasible. We found significantly higher glutathione in the cerebellum compared with the parietal gray matter. Metabolite differences between the parietal gray matter and cerebellum agree with published MRS data in adults.

**ABBREVIATIONS:** GSH = glutathione; MEGA-PRESS = Mescher-Garwood point-resolved spectroscopy; PGM = parietal gray matter; Tau = taurine; t- = total

Glutathione (GSH) is an important antioxidant in the human brain<sup>1,2</sup> and has been shown to be altered in a number of pathologies.<sup>3–7</sup> Measuring GSH is of interest in neurodegenerative

disorders<sup>8</sup> and may be a potential mechanistic biomarker for oxidative stress–related diseases and the efficacy of antioxidative treatments. Our specific interest is the quantification of GSH in the brains of children affected by neurodegenerative diseases such as ataxia telangiectasia, requiring a robust method to measure GSH levels in nonsedated children.

GSH can, in principle, be measured *in vivo* with  $^1\text{H}$ -MRS. However, due to the low concentration of GSH in the healthy human brain and in particular its overlap with higher concentration metabolites, quantification of GSH at 3T with conventional MRS sequences is controversial.<sup>9–11</sup> Spectral editing allows the removal of overlapping resonances for a direct and robust quantification of GSH.<sup>12–14</sup> While spectral editing can be used to specifically measure GSH, it is more susceptible to subject motion than conventional single-voxel MRS sequences due to longer scan times and because spectral editing is a subtraction technique that relies on consistent data acquisition.


Few studies have reported *in vivo* GSH values in healthy children,<sup>15,16</sup> and, to our knowledge, there is no study that specifically


Received June 22, 2017; accepted after revision September 13.

From the National Center for Tumor Diseases (F.R.), Partner Site Dresden, Dresden, Germany; German Cancer Research Center (F.R.), Heidelberg, Germany; Medical Faculty and University Hospital Carl Gustav Carus (F.R.), Technische Universität Dresden, Dresden, Germany; and Helmholtz Association/Helmholtz Zentrum Dresden Rossendorf (F.R.), Dresden, Germany; GE Healthcare (R.N.), Applied Science Lab Europe, Berlin, Germany; Sir Peter Mansfield Imaging Centre (R.A.D., D.P.A.), University of Nottingham, Nottingham, UK; Radiological Sciences, (R.A.D., D.P.A.), Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, UK; and National Institute for Health Research (R.A.D., D.P.A.), Nottingham Biomedical Research Centre, Nottingham, UK.

F.R. and the cost of the pediatric MRI scans were funded by the A-T Children's Project and Action for A-T.

Please address correspondence to: Rob Dineen, PhD, Radiological Sciences, University of Nottingham, Room B1435, Queen's Medical Centre, Nottingham, NG7 2UH, United Kingdom; e-mail: rob.dineen@nottingham.ac.uk

 Indicates article with supplemental on-line appendix.

 Indicates article with supplemental on-line photos.

<http://dx.doi.org/10.3174/ajnr.A5457>

measured GSH in children using spectral editing techniques or that reported GSH in the cerebellum. Therefore, the goal of this study was to investigate the feasibility of measuring GSH in healthy nonsedated children with the Mescher-Garwood point-resolved spectroscopy (MEGA-PRESS)<sup>13,17</sup> sequence and to compare GSH levels obtained in the medial parietal gray matter (PGM) with those measured in the cerebellum. To minimize subtraction errors caused by phase and frequency variations, we adapted a MEGA-PRESS postprocessing technique published by An et al<sup>17</sup> and modified it to work with our data.

## MATERIALS AND METHODS

### Subjects

Healthy children were recruited as part of an ongoing study, approved by the UK National Research Ethics Service East Midlands–Derby Committee (Reference 14/EM/1175). Informed consent was obtained from parents or guardians of participants. MRS data in the PGM were acquired in 6 children (10.0 ± 2.4 years of age; range, 7–14 years; 3 males). MR spectroscopic data in the cerebellum were acquired in 11 children (12.0 ± 2.7 years of age; range, 7–16 years; 6 males). There was no significant difference in age between the 2 groups (*t* test, *P* = .14). Structural MRI was checked by a neuroradiologist (R.A.D.) to ensure that children were neuroradiologically healthy.

### Data Acquisition

Data were acquired on a 3T MR scanner (Discovery MR750; GE Healthcare, Milwaukee, Wisconsin) equipped with a 32-channel head coil, without sedation. In addition to standard pediatric MRI preparation, younger participants were shown an animation to help prepare them for the MRI,<sup>18</sup> and participants could watch videos on an MRI-compatible monitor during the scan to improve tolerance. The MRI protocol included a 3D fast-spoiled gradient recalled T1-weighted structural MRI with 1-mm isotropic resolution for MRS planning (TR = 8.15 ms, TE = 3.172 ms, TI = 900 ms, FOV = 256 × 256 × 156 mm). Single-voxel MEGA-PRESS GSH editing was performed using TR = 2 seconds, TE = 131 ms, and 128 ON and 128 OFF acquisitions. Spectral editing was achieved with sinc-weighted Gaussian pulses with a pulse length of 20 ms (bandwidth, 64 Hz) applied at 7.5 ppm (OFF) and 4.54 ppm (ON) for editing GSH.<sup>13,17</sup> A nonedited, water-unsuppressed reference scan of 16 averages was acquired at identical acquisition parameters. MRS voxel sizes were 35 × 25 × 20 mm in the PGM and 50 × 22 × 22 mm in the cerebellum. Typical voxel locations are illustrated in Fig 1. Total acquisition time for MEGA-PRESS MRS was 9 minutes 30 seconds.

### MRS Processing

MEGA-PRESS data were processed off-line with Matlab (MathWorks, Natick, Massachusetts). The workflow steps A–H are illustrated in On-line Fig 1. The phase angles between the 32 coil elements were calculated from the average unsuppressed water signal (A). All ON and OFF spectra were subsequently phased using the water phase angles and coil-combined by using the maximum peak height of the unsuppressed water signal as weighting factors (B). The resulting coil-combined 128 ON and 128 OFF spectra were potentially out of phase relative to each other due to

subject motion and frequency drift. To correct for this, we phased individual ON and OFF spectra by maximizing the correlation of the NAA peak between the real and absolute part of the spectrum in the range of 1.87 and 2.21 ppm (C). Next, a reference ON spectrum for phase and frequency correction was created, like that described by An et al<sup>17</sup> by pair-wise aligning the 128 ON spectra in the spectral range of 1.3 and 3.3 ppm and iterative pair-wise averaging of the spectra with the smallest root mean square error (D). All 128 ON and 128 OFF spectra were subsequently aligned to this ON reference spectrum by time domain phase and frequency correction using the *fminsearch* function (<https://de.mathworks.com/help/matlab/ref/fminsearch.html>) (E) in Matlab. For the alignment, the correlation coefficient of the real part of the NAA peak (1.87–2.21 ppm) between the ON reference spectrum and the individual ON and OFF spectra was maximized. The 128 aligned ON and OFF spectra were then averaged to 1 ON and 1 OFF spectrum each (F). Individual poor-quality ON and OFF spectra were detected by calculating the correlation coefficient of the NAA peak (1.87–2.21 ppm) between the 128 ON/OFF spectra and the averaged ON/OFF spectrum, respectively (G). In our data, a correlation coefficient threshold of 0.8 (1 indicating perfect correlation) was used to pair-wise exclude individual ON and OFF spectra. Finally, the new ON and OFF average spectra were recalculated (H) and subtracted to obtain the final edited ON-OFF spectrum.

### Metabolite Quantification


Unedited MEGA-PRESS OFF spectra were analyzed between 4 and 0.2 ppm with LCModel (Version 6.3-1H; <http://www.lcmodel.com/lcmodel.shtml>)<sup>19</sup> using a basis set simulated with TARQUIN (<http://tarquin.sourceforge.net/>).<sup>20</sup> The OFF spectra were used to quantify total NAA (tNAA = NAA + *N*-acetyl aspartylglutamate), total Creatine (tCr = Cr + phosphocreatine), total Choline (tCho = glycerophosphorylcholine + phosphorylcholine), mIns, Glx, and Taurine (Tau). The edited ON-OFF MEGA-PRESS spectra were analyzed in the range of 3.6–0.2 ppm with LCModel, using a measured basis set from GSH and NAA solutions. LCModel parameters for the ON-OFF analysis are given in the On-line Appendix.

Metabolite values are reported as ratios to tCr and as water-scaled values using the unsuppressed OFF water signal. For the latter, corresponding structural T1WI was segmented via SPM software (<http://www.fil.ion.ucl.ac.uk/spm/software/spm12>) into gray matter, white matter, and CSF and aligned with the MRS volume with in-house software. Water-scaled metabolite values were corrected for CSF contamination by dividing them by 1–CSF%. Because the complex anatomic structure in the cerebellum would not allow an accurate separation of gray and white matter, we did not take their differences in water content into account. T1 and T2 correction was not performed; thus, water-scaled and CSF-corrected metabolite values are reported as institutional units.

A 2-sample *t* test assuming unequal variances was used to determine significant differences in metabolite values and ratios between the PGM and the cerebellum.

## RESULTS

The proposed GSH processing gave robust results in all spectra. On-line Fig 2 shows the edited ON-OFF spectra and correspond-



**FIG 1.** Examples of the MRS voxel placement in the PGM (A) and cerebellum (B) in two 7-year-old children. Corresponding OFF (C and D) and ON-OFF (E and F) spectra are shown below. Individual metabolite spectra fitted by LCModel are highlighted in different colors. D, The arrow highlights visible resonances that are particularly large in the cerebellum and likely belong to taurine and scyllo-inositol. Residuals of the fits (black, upper row) and estimated LCModel baselines (black, lower row) are shown for each spectrum.

ing GSH fits determined by LCModel for all subjects. An example in On-line Fig 1 illustrates the correction for phase and frequency shifts in a PGM spectrum acquired in an 11-year-old girl.


Figure 1 shows sample spectra from the PGM and cerebellum and corresponding metabolite fits for two 7-year-old children. The OFF spectra from the cerebellum show visible resonances between 3.3 and 3.5 ppm (see the arrow in Fig 1D). LCModel assigned these resonances to taurine (around 3.4 ppm) and scyllo-inositol (around 3.34 ppm), but the fitted scyllo-inositol signals were too small for reliable quantification in both the cerebellum (Cramer-Rao lower bounds,  $21\% \pm 22\%$ ) and PGM (Cramer-Rao lower bounds,  $33\% \pm 27\%$ ). We therefore only report the apparent taurine signal for the cerebellum (Cramer-Rao lower bounds,  $9\% \pm 1\%$ ) and PGM (Cramer-Rao lower bounds,  $14\% \pm 2\%$ ). However, the combined sum of Tau + scyllo-inositol showed the same trends as taurine using either water scaling or ratios (results not shown).

We found significantly higher GSH in the cerebellum compared with the PGM ( $P < .01$ ). Additionally, we found higher tCho ( $P < .01$ ), tCr ( $P < .01$ ), mIns ( $P < .01$ ), and Tau ( $P < .01$ ) in the cerebellum, whereas NAA ( $P < .01$ ) and Glx ( $P < .01$ ) were significantly higher in the PGM. Boxplots are shown in Fig 2.


Figure 3 shows the results of the metabolite ratios between the PGM and cerebellum. There was no significant difference in GSH/tCr ( $P = .93$ ). However, tNAA/tCr ( $P < .01$ ), tNAA/tCho ( $P < .01$ ), mIns/tCr ( $P = .01$ ), and Glx/tCr ( $P < .01$ ) were significantly higher in the PGM. Both tCho/tCr ( $P < .01$ ) and Tau/tCr ( $P = .02$ ) were lower in the PGM.

## DISCUSSION

We demonstrate reliable detection of glutathione levels in the parietal gray matter and cerebellum of nonsedated children using a dedicated proton MRS protocol for acquisition and postprocessing. Postpro-



**FIG 2.** Boxplots showing the water-scaled metabolite values in institutional units in the PGM and cerebellum.



**FIG 3.** Boxplots showing the metabolite ratios in the PGM and cerebellum.

cessing of GSH MEGA-PRESS MRS was challenging, mainly because the editing pulse at 4.54 ppm also eliminates most of the residual water signal in the ON spectrum; this feature makes it difficult to precisely match its phase to the OFF spectrum. This difficulty can lead to subtraction artifacts, which are most often visible around the 2-ppm area and could severely bias GSH quantification due to residual overlapping Cr signal at 3 ppm. We therefore adapted and modified a previously published postprocessing approach.<sup>17</sup> Whereas An et al<sup>17</sup> focused on the complex spectral values from the Cr, Cho, and NAA peaks for alignment of individual spectra, our processing was simplified by focusing the alignment on the real part of the NAA and

omitting zero and first-order baseline adjustments. This was performed to reduce the number of fitted parameters for a more robust parameter determination in our lower SNR spectra caused by a smaller voxel size.

To the best of our knowledge, this is the first study to compare GSH levels in the cerebrum with those found in the cerebellum in children. Few studies compared GSH levels between the cerebellum and the cerebrum in adults. In agreement with our findings, Emir et al<sup>21</sup> found higher GSH and tCr in the vermis compared with the occipital cortex and posterior cingulate in healthy adults using a short-echo STEAM sequence at 7T, albeit without T1, T2, and CSF correction. An extensive postmortem study in humans by Tong et al<sup>22</sup> showed no significant difference in GSH between the occipital and cerebellar cortices in the 1- to 18-year age group. A histologic study in mice by Kang et al<sup>23</sup> revealed slightly lower GSH in the cerebellum compared with the cortex.

Previous studies reported higher Cho and Cr levels in the cerebellum compared with the cerebrum in healthy adults,<sup>24,25</sup> in agreement with the results in our cohort of children, whereas an MR spectroscopic imaging study by Lecocq et al<sup>26</sup> found only reduced NAA in the cerebellum. Looking at metabolite ratios, several studies found lower tNAA/tCr in the cerebellum compared with the cerebrum in children<sup>27</sup> and adults,<sup>28-30</sup> in agreement with our findings. Additionally, Goryawala et al<sup>31</sup> showed lower Glx/tCr in the cerebellum in adults, in agreement with our results in children. Another noteworthy finding in this study was higher apparent Tau/tCr in the cerebellum compared with the PGM. Taurine is particularly high in infants and children in the cerebellar cortex.<sup>32,33</sup> Additionally, elevated taurine is characteristic of medulloblastomas,<sup>34</sup> mainly originating in the cerebellum of children.

A limitation of this study is the relatively small sample size and the use of different subjects to scan the PGM and the cerebellum. Scanning the PGM and cerebellum in each subject would have allowed a pair-wise statistical analysis and likely reduced variability. We were, however, limited by time constraints in the MRI protocol due to the long acquisition time of GSH MEGA-PRESS MRS. Additionally, the MRS voxel in the cerebellum was relatively large, to ensure high-enough SNR for GSH quantification, thus having a relatively heterogeneous tissue composition, including the cerebellar gray matter (vermis and cortex) and the underlying cerebellar white matter.

## CONCLUSIONS

We demonstrated that GSH measurement in nonsedated children is feasible. We found higher GSH in the cerebellum compared with the PGM. Differences in the other metabolites agree with published MRS data in adults; this finding suggests no major metabolic maturation effect from 7 years of age and older in our dataset.

Disclosures: Felix Raschke—RELATED: Grant: A-T Children's Project and Action for A-T, Comments: This work was supported by a research grant awarded by the 2 named charities\*; UNRELATED: Support for Travel to Meetings for the Study or Other Purposes: Guarantors of Brain, Comments: travel grant to support travel to the International Society for Magnetic Resonance in Medicine meeting in 2015. Ralph Noeske—UNRELATED: Employment: GE Healthcare. Robert A. Dineen—RELATED: Grant: A-T Children's Project and Action for A-T.\* Dorothee P. Auer—RELATED: Grant: A-T Children's Project and Action for A-T\*; UNRELATED: Grants/Grants Pending: UK charities, UK research councils, National Institute for Health Research, UK funding.\* \*Money paid to the institution.

## REFERENCES

1. Dringen R. **Metabolism and functions of glutathione in brain.** *Prog Neurobiol* 2000;62:649–71 CrossRef Medline
2. Mazzetti AP, Fiorile MC, Primavera A, et al. **Glutathione transferases and neurodegenerative diseases.** *Neurochem Int* 2015;82:10–18 CrossRef Medline
3. An L, Dani KA, Shen J, et al; Natural History of Stroke Investigators. **Pilot results of in vivo brain glutathione measurements in stroke patients.** *J Cereb Blood Flow Metab* 2012;32:2118–21 CrossRef Medline
4. Choi IY, Lee SP, Denney DR, et al. **Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T.** *Mult Scler* 2011;17:289–96 CrossRef Medline
5. Do KQ, Trabesinger AH, Kirsten-Krüger M, et al. **Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.** *Eur J Neurosci* 2000;12:3721–28 CrossRef Medline
6. Matsuzawa D, Obata T, Shirayama Y, et al. **Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study.** *PLoS One* 2008;3:e1944 CrossRef Medline
7. Srinivasan R, Ratiney KH, Hammond-Rosenbluth KE, et al. **MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis.** *Magn Reson Imaging* 2010;28:163–70 CrossRef Medline
8. Aoyama K, Nakaki T. **Impaired glutathione synthesis in neurodegeneration.** *Int J Mol Sci* 2013;14:21021–44 CrossRef Medline
9. Sanaei Nezhad F, Anton A, Parkes LM, et al. **Quantification of glutathione in the human brain by MR spectroscopy at 3 Tesla: comparison of PRESS and MEGA-PRESS.** *Magn Reson Med* 2017;78:1257–66 CrossRef Medline
10. Oz G, Tkáč I. **Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for neurochemical profiling at 4 T: validation in the cerebellum and brainstem.** *Magn Reson Med* 2011;65:901–10 CrossRef Medline
11. Mekle R, Mlynárik V, Gambarota G, et al. **MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T.** *Magn Reson Med* 2009;61:1279–85 CrossRef Medline
12. Mescher M, Merkle H, Kirsch J, et al. **Simultaneous in vivo spectral editing and water suppression.** *NMR Biomed* 1998;11:266–72 Medline
13. Terpstra M, Henry PG, Gruetter R. **Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra.** *Magn Reson Med* 2003;50:19–23 CrossRef Medline
14. Trabesinger AH, Weber OH, Duc CO, et al. **Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering.** *Magn Reson Med* 1999;42:283–89 Medline
15. Degnan AJ, Ceschin R, Lee V, et al. **Early metabolic development of posteromedial cortex and thalamus in humans analyzed via in vivo quantitative magnetic resonance spectroscopy.** *J Comp Neurol* 2014;522:3717–32 CrossRef Medline
16. Kreis R, Hofmann L, Kuhlmann B, et al. **Brain metabolite composition during early human brain development as measured by quantitative in vivo 1H magnetic resonance spectroscopy.** *Magn Reson Med* 2002;48:949–58 CrossRef Medline
17. An L, Zhang Y, Thomasson DM, et al. **Measurement of glutathione in normal volunteers and stroke patients at 3T using J-difference spectroscopy with minimized subtraction errors.** *J Magn Reson Imaging* 2009;30:263–70 CrossRef Medline
18. Szeszak S, Man R, Love A, et al. **Animated educational video to prepare children for MRI without sedation: evaluation of the appeal and value.** *Pediatr Radiol* 2016;46:1744–50 CrossRef Medline
19. Provencher SW. **Estimation of metabolite concentrations from localized in vivo proton NMR spectra.** *Magn Reson Med* 1993;30:672–79 CrossRef Medline
20. Wilson M, Reynolds G, Kauppinen RA, et al. **A constrained least-squares approach to the automated quantitation of in vivo 1H magnetic resonance spectroscopy data.** *Magn Reson Med* 2011;65:1–12 CrossRef Medline
21. Emir UE, Auerbach EJ, Van De Moortele PF, et al. **Regional neurochemical profiles in the human brain measured by 1H MRS at 7 T using local B1 shimming.** *NMR Biomed* 2012;25:152–60 CrossRef Medline
22. Tong J, Fitzmaurice PS, Moszczynska A, et al. **Do glutathione levels decline in aging human brain?** *Free Radic Biol Med* 2016;93:110–17 CrossRef Medline
23. Kang Y, Viswanath V, Jha N, et al. **Brain gamma-glutamyl cysteine synthetase (GCS) mRNA expression patterns correlate with regional-specific enzyme activities and glutathione levels.** *J Neurosci Res* 1999;58:436–41 Medline
24. Pouwels PJ, Frahm J. **Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS.** *Magn Reson Med* 1998;39:53–60 CrossRef Medline
25. Jacobs MA, Horská A, van Zijl PC, et al. **Quantitative proton MR spectroscopic imaging of normal human cerebellum and brain stem.** *Magn Reson Med* 2001;46:699–705 Medline
26. Lecocq A, Le Fur Y, Maudsley AA, et al. **Whole-brain quantitative mapping of metabolites using short echo three-dimensional proton MRSI.** *J Magn Reson Imaging* 2015;42:280–89 CrossRef Medline
27. Cichočka M, Kozub J, Karcz P, et al. **Regional differences in the concentrations of metabolites in the brain of healthy children: a proton magnetic resonance spectroscopy ((1)HMRS) study.** *Polish J Radiol* 2016;81:473–77 CrossRef Medline
28. Granata F, Pandolfo G, Vinci S, et al. **Proton magnetic resonance spectroscopy (H-MRS) in chronic schizophrenia: a single-voxel study in three regions involved in a pathogenetic theory.** *Neuroradiol J* 2013;26:277–83 CrossRef Medline
29. Safriel Y, Pol-Rodriguez M, Novotny EJ, et al. **Reference values for long echo time MR spectroscopy in healthy adults.** *AJNR Am J Neuroradiol* 2005;26:1439–45 Medline
30. Sabati M, Sheriff S, Gu M, et al. **Multivendor implementation and comparison of volumetric whole-brain echo-planar MR spectroscopic imaging.** *Magn Reson Med* 2015;74:1209–20 CrossRef Medline
31. Goryawala MZ, Sheriff S, Maudsley A. **Regional distributions of brain glutamate and glutamine in normal subjects.** *NMR Biomed* 2016;29:1108–16 CrossRef Medline
32. Pouwels PJ, Brockmann K, Kruse B, et al. **Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS.** *Pediatr Res* 1999;46:474–85 CrossRef Medline
33. Blüml S, Wisnowski JL, Nelson MD Jr, et al. **Metabolic maturation of the human brain from birth through adolescence: insights from in vivo magnetic resonance spectroscopy.** *Cereb Cortex* 2013;23:2944–55 CrossRef Medline
34. Davies NP, Wilson M, Harris LM, et al. **Identification and characterisation of childhood cerebellar tumours by in vivo proton MRS.** *NMR Biomed* 2008;21:908–18 CrossRef Medline